earn rearview mirror publish updat
model hand compani follow recent file includ
ghdx
buy pt formal updat stand-alon model
reflect result upwardli revis outlook time
incorpor effect pend ghdx acquisit model
revenu forecast move respect
pt move impli pro-forma rev
includ ghdx account share issu par high-
ghdx hold pt rais ep forecast
respect model assum revenue compound-annual-growth-rate
pt unchang line impli takeout time offer
hold pt rais ep forecast
respect pt move
impli ep ev/ufcf
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
summari chang
pleas see import disclosur inform page report
pleas see import disclosur inform page report
thermo fisher scientif inc histor project statement incomedollar million except per share amountshistor net product incom expens share share analysisgross sg oper margin incom incom net growth analysisnet sg oper incom net dilut thermo fisher scientif jefferi llc equiti research
pleas see import disclosur inform page report
corp histor project statement incomedollar million except per share amountshistor net product expens share share analysisgross analysisnet jefferi llc equiti research
pleas see import disclosur inform page report
genom health inc histor project statement incom million except per share histor net product expens share share ebitda analysisgross sell oper incom net growth analysisnet genom health jefferi llc thermo fisher scientif inc
nopat compound-annual-growth-rate next decad
pthn total ebita synergi
price target impli price-to-earnings ep
ev ebitda
pthn faster synergi captur
bolt-on thru
price target base price-to-earnings ep ev
ebitda
organ revenu growth well target
disrupt sales/suppli chain due tariff
price target impli price-to-earnings ep
 robust profil attract merit howev
see less room rel absolut multipl expans
statu out-year ep power
pleas see import disclosur inform page report
increment margin
ebit margin ebit margin
price target impli enterpris valu
revenu in-lin specialti lab peer
revenu faster prostat
price target ev revenu
core us breast
commerci reimburs progress prostat
slower ou trend german reimburs
acceler sale forc invest support
price target ev revenu
tailorx data last yr game-chang ghdx
solidifi monopoli early-stag breast cancer
structur lift growth profil high-degre
visibl growth elev focu
profit fundament stori certainli stronger
mani other dx see less variabl around
guidanc prior yr remain hold given
much progress appear reflect stock
partnership biocarti expect launch
pleas see import disclosur inform page report
rev test
rev test
realiz
valu futur pipelin test
price target impli equiti valu
rev discount back
acceler payor coverag adopt expand
launch within next year competit liquid biopsi
npv pipelin
ep power rev ebit
potenti strateg take-out interest
higher expect oper expens support
emerg competit threat blood-bas
test liquid biopsi innov
financ fund pipelin
ceo/cfo key leadership departur
price target impli equiti valu
test earli detect colorect cancer
offer viabl altern exist screen
techniqu colonoscopi fit/fobt signific
potenti drastic improv complianc becom
gold standard front-lin screen test estim
cologuard address market alon
expand label age group expect
acceler penetr co-promot
label indic use high-risk patient
penetr larg health system
pleas see import disclosur inform page report
